{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:23:00Z","timestamp":1718842980841},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,18]]},"DOI":"10.7759\/cureus.62638","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T01:40:17Z","timestamp":1718761217000},"source":"Crossref","is-referenced-by-count":0,"title":["Novel Use of Ivabradine for Persistent Sinus Tachycardia in a Patient on Extracorporeal Life Support With Right Ventricular Dysfunction"],"prefix":"10.7759","author":[{"given":"Kristina","family":"Akopyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aman","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindaugas","family":"Rackauskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Gries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Emtiazjoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biplab K","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy128","article-title":"Inappropriate sinus tachycardia","volume":"21","author":"Olshansky B","year":"2019","unstructured":"Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. Europace. 2019, 21:194-207. 10.1093\/europace\/euy128","journal-title":"Europace"},{"key":"ref2","article-title":"Sinus tachycardia","author":"Henning A","year":"2024","unstructured":"Henning A, Krawiec C. Sinus tachycardia. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278477","article-title":"Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial","volume":"310","author":"Morelli A","year":"2013","unstructured":"Morelli A, Ertmer C, Westphal M, et al.. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013, 310:1683-91. 10.1001\/jama.2013.278477","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.04.019","article-title":"Inappropriate sinus tachycardia: etiology, pathophysiology, and management: JACC review topic of the week","volume":"79","author":"Ahmed A","year":"2022","unstructured":"Ahmed A, Pothineni NV, Charate R, et al.. Inappropriate sinus tachycardia: etiology, pathophysiology, and management: JACC review topic of the week. J Am Coll Cardiol. 2022, 79:2450-62. 10.1016\/j.jacc.2022.04.019","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000335","article-title":"Treatment for inappropriate sinus tachycardia","volume":"24","author":"Salazar Adum JP","year":"2017","unstructured":"Salazar Adum JP, Arora R. Treatment for inappropriate sinus tachycardia. Am J Ther. 2017, 24:e574-8. 10.1097\/MJT.0000000000000335","journal-title":"Am J Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000112412","article-title":"The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population","volume":"110","author":"Ferrari R","year":"2008","unstructured":"Ferrari R, Ford I, Fox K, Steg PG, Tendera M. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology. 2008, 110:271-82. 10.1159\/000112412","journal-title":"Cardiology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.06.024","article-title":"Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure","volume":"166","author":"Fox K","year":"2013","unstructured":"Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013, 166:654-661.e6. 10.1016\/j.ahj.2013.06.024","journal-title":"Am Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"SHIFT Investigators","year":"2010","unstructured":"SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010, 376:1988. 10.1016\/S0140-6736(10)61198-1","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-18-1184","article-title":"Ivabradine for the treatment of cardiovascular diseases","volume":"83","author":"Ide T","year":"2019","unstructured":"Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the treatment of cardiovascular diseases. Circ J. 2019, 83:252-60. 10.1253\/circj.CJ-18-1184","journal-title":"Circ J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000003045","article-title":"Heart rate control during experimental sepsis in mice: comparison of ivabradine and \u03b2-blockers","volume":"132","author":"Bedet A","year":"2020","unstructured":"Bedet A, Voiriot G, Ternacle J, Marcos E, Adnot S, Derumeaux G, Mekontso Dessap A. Heart rate control during experimental sepsis in mice: comparison of ivabradine and \u03b2-blockers. Anesthesiology. 2020, 132:321-9. 10.1097\/ALN.0000000000003045","journal-title":"Anesthesiology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201312-446FR","article-title":"Management of acute right ventricular failure in the intensive care unit","volume":"11","author":"Ventetuolo CE","year":"2014","unstructured":"Ventetuolo CE, Klinger JR. Management of acute right ventricular failure in the intensive care unit. Ann Am Thorac Soc. 2014, 11:811-22. 10.1513\/AnnalsATS.201312-446FR","journal-title":"Ann Am Thorac Soc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/157489009787260016","article-title":"Ivabradine: cardiovascular effects","volume":"4","author":"Rognoni A","year":"2009","unstructured":"Rognoni A, Bertolazzi M, Macci\u00f2 S, Rognoni G. Ivabradine: cardiovascular effects. Recent Pat Cardiovasc Drug Discov. 2009, 4:61-6. 10.2174\/157489009787260016","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003703","article-title":"Use of \u03b2-blockers in pulmonary hypertension","volume":"10","author":"Perros F","year":"2017","unstructured":"Perros F, de Man FS, Bogaard HJ, et al.. Use of \u03b2-blockers in pulmonary hypertension. Circ Heart Fail. 2017, 10:10.1161\/CIRCHEARTFAILURE.116.003703","journal-title":"Circ Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2019.15.2","article-title":"Right ventricular failure: pathophysiology, diagnosis and treatment","volume":"5","author":"Arrigo M","year":"2019","unstructured":"Arrigo M, Huber LC, Winnik S, et al.. Right ventricular failure: pathophysiology, diagnosis and treatment. Card Fail Rev. 2019, 5:140-6. 10.15420\/cfr.2019.15.2","journal-title":"Card Fail Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2019-0317OC","article-title":"Heart rate reduction improves right ventricular function and fibrosis in pulmonary hypertension","volume":"63","author":"Ishii R","year":"2020","unstructured":"Ishii R, Okumura K, Akazawa Y, et al.. Heart rate reduction improves right ventricular function and fibrosis in pulmonary hypertension. Am J Respir Cell Mol Biol. 2020, 63:843-55. 10.1165\/rcmb.2019-0317OC","journal-title":"Am J Respir Cell Mol Biol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/265558-novel-use-of-ivabradine-for-persistent-sinus-tachycardia-in-a-patient-on-extracorporeal-life-support-with-right-ventricular-dysfunction","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T01:40:20Z","timestamp":1718761220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/265558-novel-use-of-ivabradine-for-persistent-sinus-tachycardia-in-a-patient-on-extracorporeal-life-support-with-right-ventricular-dysfunction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.62638","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,18]]}}}